+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sjogren's Syndrome (SS) - Epidemiology Forecast to 2028

  • ID: 4827852
  • Report
  • August 2019
  • Region: Global
  • 105 pages
  • DelveInsight
1 of 2
‘Sjogren’s Syndrome (SS)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Sjogren’s Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Sjogren’s Syndrome Epidemiology
The Sjogren’s Syndrome epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Sjogren’s Syndrome are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Sjogren’s Syndrome Epidemiology Segmentation
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by Diagnosed Prevalent cases, Gender-specific cases, Type-specific cases [Primary Sjogren’s Syndrome (pSS), Secondary Sjogren’s Syndrome (sSS)] and Severity-specific cases [Mild and Moderate to Severe] in the 7MM.

According to the author, the total diagnosed prevalent cases of Sjogren’s Syndrome were 3,270,396 in 2017 in 7MM.

Report Scope
  • The report covers a detailed overview of Sjogren’s Syndrome explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Sjogren’s Syndrome.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity-specific cases of Sjogren’s Syndrome in 7MM.
Key Strengths
  • 10 Year Forecast of Sjogren’s Syndrome epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Sjogren’s Syndrome
  • Prevalent Cases according to segmentation: type-specific cases and severity-specific cases
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Sjögren’s Syndrome (SS): Epidemiology Overview at a Glance
2.1. Patient Share (%) Distribution of SS in 2017
2.2. Patient Share (%) Distribution of SS in 2028

3. Disease Overview: Sjögren’s syndrome
3.1. Introduction
3.2. Classification of Sjogren’s Syndrome
3.3. Signs and Symptoms
3.4. Etiology
3.5. Pathogenesis
3.6. Biomarkers in Sjogren’s Syndrome
3.7. Diagnosis of Sjogren’s Syndrome
3.7.1. Differential Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Diagnosed Prevalent Patient Population of Sjögren’s Syndrome
4.3. Country Wise-Epidemiology of Sjögren’s syndrome
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States
4.4.3. Gender-Specific Cases of Sjögren’s syndrome in the US
4.4.4. Type-Specific Cases of Sjögren’s syndrome in the US
4.4.5. Severity-Specific Cases of Sjögren’s syndrome in the US
4.5. Germany
4.5.1. Assumptions and Rationale
4.5.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany
4.5.3. Gender-Specific Cases of Sjögren’s syndrome in Germany
4.5.4. Type-Specific Cases of Sjögren’s syndrome in Germany
4.5.5. Severity-Specific Cases of Sjögren’s syndrome in Germany
4.6. France
4.6.1. Assumptions and Rationale
4.6.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in France
4.6.3. Gender-Specific Cases of Sjögren’s syndrome in France
4.6.4. Type-Specific Cases of Sjögren’s syndrome in France
4.6.5. Severity-Specific Cases of Sjögren’s syndrome in France
4.7. Italy
4.7.1. Assumptions and Rationale
4.7.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy
4.7.3. Gender-Specific Cases of Sjögren’s syndrome in Italy
4.7.4. Type-Specific Cases of Sjögren’s syndrome in Italy
4.7.5. Severity-Specific Cases of Sjögren’s syndrome in Italy
4.8. Spain
4.8.1. Assumptions and Rationale
4.8.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain
4.8.3. Gender-Specific Cases of Sjögren’s syndrome in Spain
4.8.4. Type-Specific Cases of Sjögren’s syndrome in Spain
4.8.5. Severity-Specific Cases of Sjögren’s syndrome in Spain
4.9. United Kingdom
4.9.1. Assumptions and Rationale
4.9.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom
4.9.3. Gender-Specific Cases of Sjögren’s syndrome in the United Kingdom
4.9.4. Type-Specific Cases of Sjögren’s syndrome in the UK
4.9.5. Severity-Specific Cases of Sjögren’s syndrome in the United Kingdom
4.10. Japan
4.10.1. Assumptions and Rationale
4.10.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan
4.10.3. Gender-Specific Cases of Sjögren’s syndrome in Japan
4.10.4. Type-Specific Cases of Sjögren’s syndrome in Japan
4.10.5. Severity-Specific Cases of Sjögren’s syndrome in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. Appendix

9. Report Methodology

10. Capabilities

11. Disclaimer

12. About the Author

13. Disclaimer

List of Tables
Table 1: American-European Consensus Group Criteria- Revised international classification criteria for Sjögren’s syndrome
Table 2: Revised rules for classification - American-European Consensus Group Criteria
Table 3: ACR/EULAR criteria
Table 4: Selected Non-HLA genes implicated in SS
Table 5: Biomarkers in Primary Sjogren’s syndrome
Table 6: Diagnostic tests to evaluate sicca symptoms in patients with Sjogren’s Syndrome
Table 7: Evaluation of Dry Eye
Table 8: Comparison of the Revised AECG Classification criteria and the ACR Classification criteria for Sjögren's syndrome
Table 9: Diagnosed Prevalent Patient Population of Sjögren’s syndrome in 7MM (2017–2028)
Table 10: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 11: Gender-specific cases of Sjögren’s syndrome in the United States (2017–2028)
Table 12: Type-specific Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 13: Severity-specific Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 14: Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 15: Gender-specific cases of Sjögren’s syndrome in Germany (2017–2028)
Table 16: Type-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 17: Severity-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 18: Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Table 19: Gender-specific cases of Sjögren’s syndrome in France (2017–2028)
Table 20: Type-specific Cases of Sjögren’s syndrome in France (2017–2028)
Table 21: Severity-specific Cases of Sjögren’s syndrome in France (2017–2028)
Table 22: Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 23: Gender-specific cases of Sjögren’s syndrome in Italy (2017–2028)
Table 24: Type-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 25: Severity-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 26: Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 27: Gender-specific cases of Sjögren’s syndrome in Spain (2017–2028)
Table 28: Type-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 29: Severity-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 30: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 31: Gender-specific cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 32: Type-specific Cases of Sjögren’s syndrome in the UK (2017–2028)
Table 33: Severity-specific Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 34: Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Table 35: Gender-specific cases of Sjögren’s syndrome in Japan (2017–2028)
Table 36: Type-specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Table 37: Severity-specific Cases of Sjögren’s syndrome in Japan (2017–2028)

List of Figures
Figure 1: Clinical spectrum Sjogren’s syndrome
Figure 2: The pathogenesis of autoimmune epitelitis as a potential explanation for Sjogren’s Syndrome
Figure 3: Interplay of immune and non-immune factors in the pathophysiology of Sjogren’s Syndrome
Figure 4: Diagnosed Prevalent Patient Population of Sjögren’s syndrome in 7MM (2017–2028)
Figure 5: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States (2017–2028)
Figure 6: Gender-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 7: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 8: Severity-specific Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 9: Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 10: Gender-specific of Sjögren’s syndrome in Germany (2017–2028)
Figure 11: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 12: Severity-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 13: Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Figure 14: Gender-specific Cases of Sjögren’s syndrome in France (2017–2028)
Figure 15: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Figure 16: Severity-specific Cases of Sjögren’s syndrome in France (2017–2028)
Figure 17: Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 18: Gender-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 19: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 20: Severity-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 21: Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 22: Gender-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 23: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 24: Severity-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 25: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Figure 26: Gender-specific Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Figure 27: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the UK (2017–2028)
Figure 28: Severity-specific Cases of Sjögren’s syndrome in the UK (2017–2028)
Figure 29: Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 30: Gender-specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 31: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 32: Severity -specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 33: Unmet Needs of Sjogren’s syndrome
Figure 34: Market Drivers of Sjogren’s syndrome
Figure 33: Market Barriers of Sjogren’s syndrome
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll